Clinical Trial Update: RSV F Dose-Ranging Study in Women [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial of an RSV F protein-based vaccine in women has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• RSV F vaccine (RSV F protein vaccine)

Snippet

Sponsor: Novavax | Conditions: Respiratory Syncytial Virus Infections | Phase 2 | Status: COMPLETED